BREAKING: Coronavirus Vaccine Breakthrough Shows "promising' Safety and Immune Response!!!!!


Power Poster
Early trials for Moderna's vaccine show it works to trigger an immune response, a new study says

Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.

These early results, published in the New England Journal of Medicine on Tuesday, showed that the vaccine worked to trigger an immune response with mild side effects -- fatigue, chills, headache, muscle pain, pain at the injection site -- becoming the first US vaccine candidate to publish results in a peer-reviewed medical journal.

I think this deserved its own thread, very good news to hear! It's breaking news on all major news networks! If I'm not mistaken this is our first true breakthrough!!!
Last edited:


Staff member
Beware of "miracle cure" or "vaccine on its way" stories. This virus has only been on the radar for 6 months. You do not go from zero to vaccine production in six months, especially when dealing with a chimeric virus containing protein sequences from both SARS and HIV, neither of which have had a successful vaccine developed despite years of research.

Pharmaceutical companies, on the other hand, love to see their stock go up.

Just don't get your hopes up, is all I'm saying.


Power Poster
Well the fact that every test subject had an immune response is quite significant.

Not saying we're weeks or months away for a vaccine. But we leaped the first milestone.

Very mild symptoms. Now we wait and see for long term side effects.


Power Poster
First Phase 3 clinical trial of a coronavirus vaccine in the United States begins

The investigational vaccine was developed by the biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial is to be conducted at nearly 100 US research sites, according to Moderna. The first patient was dosed at a site in Savannah, Georgia.

The trial is expected to enroll about 30,000 adult volunteers and evaluates the safety of the Moderna/NIH vaccine and whether it can prevent symptomatic Covid-19 after two doses, among other outcomes. Volunteers will receive either two 100 microgram injections of the vaccine or a placebo about 28 days apart. Investigators and participants will not know who has received the vaccine.

Results from a Phase 1 trial of the vaccinepublished earlier this month in the New England Journal of Medicine found it induced immune responses in all of the volunteers and was generally safe. It had mild side effects, including fatigue, chills, headache, muscle pain, pain at the injection site.